News | September 22, 2010

Core Curriculum Published for Structural Heart Disease Treatment

September 23, 2010 – The first consensus document for treating structural heart disease has been published by the Society for Cardiovascular Angiography and Interventions (SCAI). The core curriculum and the results of a survey of physicians and training doctors were published Tuesday in Catheterization and Cardiovascular Interventions and JACC Cardiovascular Interventions.

The curriculum, which was endorsed by the American College of Cardiology Foundation and written by interventional specialists from multiple regions, defines training and credentialing requirements along with program standards for practitioners.

Interventional treatments have evolved rapidly during the past decade, and therapies are helping more patients who previously had to undergo open-heart surgery, or who could not be treated at all. With such rapid advancement, SCAI identified a need for uniformity across training programs and specific credentials and standards for practitioners. Currently, a lack of comprehensive training programs prohibits many practitioners from treating structural heart disease, according to the SCAI survey of 107 U.S.-based interventional cardiologists.

"The primary goal of the core curriculum is to provide patients with the highest level of care and treatment available," said Carlos Ruiz, M.D., Ph.D., FSCAI, professor of pediatrics and medicine and director of the division of congenital and structural heart disease at Lenox Hill Heart and Vascular Institute of New York, and lead author of the core curriculum. "The core curriculum will serve training centers and practitioners dedicated to growing their knowledge and skill base for structural heart disease interventions and provide a forum to discuss the latest treatment advancements for structural heart disease to advance and improve patient care."

The curriculum outlines specific training recommendations and skill requirements, including:

• Superb basic catheterization skills with the ability to achieve unusual types of vascular access and manipulate various catheters, balloons and other devices.

• The ability to competently handle potential complications.

• A knowledge base and interventional skills for a variety of complex structural heart diseases, including appropriate device selection, imaging needs, stenting techniques, managing complications and acute and long-term post-procedural care.

"As structural heart disease procedures advance and become increasingly common, it is essential that practitioners acquire the right set of skills and knowledge base," said SCAI Past President Ted Feldman, M.D., FSCAI, director of cardiac catheterization at Evanston Northwestern Healthcare in Evanston, Ill., and chair of the Structural Heart Disease Council. "Patient care will benefit from those who acquire the skills and training outlined in the core curriculum document."

For more information: www.SCAI.org

Related Content

Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Overlay Init